Asthana O P, Woodcock B G, Wenchel M, Frömming K H, Schwabe L, Rietbrock N
Arzneimittelforschung. 1984;34(4):498-502.
The absorption, pharmacokinetics and effect on PQ-intervals of verapamil (Isoptin) administered as buccal tablet (20 mg), oral capsule (80-120 mg) and as an intravenous injection (5 mg) have been determined in 7 healthy subjects. Hysteresis plots of the percentage change in PQ-interval and serum concentration indicate that the efficacy of verapamil after buccal and intravenous application, as in earlier findings with sublingual verapamil tablets, was higher than after oral application. Thus the serum concentration-response curve after oral application is displaced towards the right reflecting lower potency. This phenomenon has been attributed by other workers to a stereospecific metabolism of the more active L-isomer during first pass through the liver, but competition at the receptor with metabolites cannot yet be ruled out. The rate of absorption, T1/2(alpha), terminal elimination half-life T1/2(gamma), and tmax of the buccal tablet was not significantly different from the oral capsule. The absolute bioavailability of the buccal preparation (37%) was slightly greater than the oral capsule (33%) and both had higher bioavailability than observed in earlier studies on verapamil dragees (10-20%). Thus, although the buccal tablet was alkalinised and had a rapid disintegration in vitro, characteristics thought to increase buccal uptake, the bioavailability is still much less then 100%.
在7名健康受试者中测定了以颊含片(20毫克)、口服胶囊(80 - 120毫克)和静脉注射(5毫克)给药的维拉帕米(异搏定)的吸收、药代动力学以及对PQ间期的影响。PQ间期和血清浓度变化百分比的滞后图表明,颊内和静脉给药后维拉帕米的疗效,如同早期舌下含服维拉帕米片的研究结果一样,高于口服给药后的疗效。因此,口服给药后的血清浓度 - 反应曲线向右移位,反映出效力较低。其他研究人员将这种现象归因于更具活性的L - 异构体在首次通过肝脏时的立体特异性代谢,但受体与代谢物之间的竞争尚未排除。颊含片的吸收速率、α半衰期(T1/2(α))、终末消除半衰期(T1/2(γ))和达峰时间(tmax)与口服胶囊没有显著差异。颊内制剂的绝对生物利用度(37%)略高于口服胶囊(33%),两者的生物利用度均高于早期维拉帕米糖衣丸研究中观察到的数值(10 - 20%)。因此,尽管颊含片经过碱化处理且在体外快速崩解,这些特性被认为可增加颊内吸收,但生物利用度仍远低于100%。